Loading stock data…
$4.25+0.05 (+1.19%)
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally.
EDAP TMS S.A. in the Healthcare sector is trading at $4.25 with a market capitalization of $187M. Wall Street consensus targets $8.80 (5 analysts), implying a +107.1% move over the next 12 months. The stock is currently 34% below its 52-week high of $6.40, remaining 3.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.20M↓ | $17.81M↓ | $51.61M↑ | $16.28M↑ | $9.51M |
| Gross Profit | $7.34M↓ | $8.15M↓ | $21.86M↑ | $7.01M↑ | $4.86M |
| Operating Income | -$8.03M↓ | -$7.37M↑ | -$17.98M↓ | -$5.78M↑ | -$6.62M |
| Net Income | -$14.49M↓ | -$9.08M↑ | -$22.41M↓ | -$5.88M↑ | -$6.41M |
EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and inter...